RIGL(Rigel Pharmaceuticals, Inc.) · 财务报表

RIGL(Rigel Pharmaceuticals, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$149.24M$120.24M$116.88M$179.28M$294.28M
毛利润$148.15M$118.49M$109.77M$160.63M$274.66M
营业利润−$12.50M−$55.55M−$20.49M$24.19M$125.47M
净利润−$17.91M−$58.57M−$25.09M$17.48M$367.02M
经营现金流$5.88M−$73.76M−$5.74M$31.47M$75.66M
自由现金流$5.25M−$74.21M———
摊薄每股收益$-1.10$-3.44$-1.44$0.99$19.48

Rigel Pharmaceuticals, Inc. RIGL